Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 260

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Chemotherapy and COVID-19 Outcomes in Patients With Cancer

Open access
Jee, Justin, Foote, Michael B., Lumish, Melissa, Stonestrom, Aaron J., Wills, Beatriz, Narendra, Varun, Avutu, Viswatej, Murciano-Goroff, Yonina R., Chan, Jason E., Derkach, Andriy, Philip, John, Belenkaya, Rimma, Kerpelev, Marina, Maloy, Molly, Watson, Adam, Fong, Chris, Janjigian, Yelena, Diaz, Luis A., Bolton, Kelly L., Pessin, Melissa S. · 2020 · Journal of Clinical Oncology

Abstract

PURPOSE: Coronavirus-2019 (COVID-19) mortality is higher in patients with cancer than in the general population, yet the cancer-associated risk factors for COVID-19 adverse outcomes are not fully characterized. PATIENTS AND METHODS: We reviewed clinical characteristics and outcomes from patients with cancer and concurrent COVID-19 at Memorial Sloan Kettering Cancer Center until March 31, 2020 (n = 309), and observed clinical end points until April 13, 2020. We hypothesized that cytotoxic chemotherapy administered within 35 days of a COVID-19 diagnosis is associated with an increased hazard ratio (HR) of severe or critical COVID-19. In secondary analyses, we estimated associations between specific clinical and laboratory variables and the incidence of a severe or critical COVID-19 event. RESULTS: Cytotoxic chemotherapy administration was not significantly associated with a severe or critical COVID-19 event (HR, 1.10; 95% CI, 0.73 to 1.60). Hematologic malignancy was associated with increased COVID-19 severity (HR, 1.90; 95% CI, 1.30 to 2.80). Patients with lung cancer also demonstrated higher rates of severe or critical COVID-19 events (HR, 2.0; 95% CI, 1.20 to 3.30). Lymphopenia at COVID-19 diagnosis was associated with higher rates of severe or critical illness (HR, 2.10; 95% CI, 1.50 to 3.10). Patients with baseline neutropenia 14-90 days before COVID-19 diagnosis had worse outcomes (HR, 4.20; 95% CI, 1.70 to 11.00). Findings from these analyses remained consistent in a multivariable model and in multiple sensitivity analyses. The rate of adverse events was lower in a time-matched population of patients with cancer without COVID-19. CONCLUSION: Recent cytotoxic chemotherapy treatment was not associated with adverse COVID-19 outcomes. Patients with active hematologic or lung malignancies, peri–COVID-19 lymphopenia, or baseline neutropenia had worse COVID-19 outcomes. Interactions among antineoplastic therapy, cancer type, and COVID-19 are complex and warrant further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.20.01307

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 260

Metadata

Authors
Jee, J., Foote, M. B., Lumish, M., Stonestrom, A. J., Wills, B., Narendra, V., Avutu, V., Murciano-Goroff, Y. R., Chan, J. E., Derkach, A., Philip, J., Belenkaya, R., Kerpelev, M., Maloy, M., Watson, A., Fong, C., Janjigian, Y., Diaz, L. A., Bolton, K. L., & Pessin, M. S.
Venue
Journal of Clinical Oncology
Published
2020-10-20
Volume
38
Issue
30
Pages
3538-3546
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3049425660
Cited by
260
References
16
FWCI
18.61
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chemotherapy and COVID-19 Outcomes in Patients With Cancer. https://app.cochat.ai/papers/10.1200/jco.20.01307
The paper
Jee, J., Foote, M. B., Lumish, M., Stonestrom, A. J., Wills, B., Narendra, V., Avutu, V., Murciano-Goroff, Y. R., Chan, J. E., Derkach, A., Philip, J., Belenkaya, R., Kerpelev, M., Maloy, M., Watson, A., Fong, C., Janjigian, Y., Diaz, L. A., Bolton, K. L., & Pessin, M. S. (2020). Chemotherapy and COVID-19 Outcomes in Patients With Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.01307

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.